#1
#1 out of 1
health9h ago
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
- A new daily pill, daraxonrasib, targets the KRAS gene and shows promising survival in pancreatic cancer patients.
- In early Phase 1/2 data, overall survival for patients on daraxonrasib reached about 13.2 months, near doubling standard care.
- About one-third of patients with the KRAS G12 mutation showed an objective tumor response to the drug.
- A 30% incidence of severe side effects, including rash and GI issues, accompanies daraxonrasib.
- FDA fast-tracked limited approval raised access and equity questions for patients and providers.
- Cost and affordability remain unresolved as doctors anticipate insurance coverage challenges.
- Researchers aim to broaden use earlier in treatment and explore combinations with immunotherapy or surgery.
- Revolution Medicines plans a full Phase 3 readout at the ASCO annual meeting to shape future approvals.
- Experts see potential for the drug to alter the standard of care for PDAC if earlier use proves beneficial.
Vote 0